Short-course radiotherapy in stage IV rectal cancer with resectable disease
Short-course radiotherapy in stage IV rectal cancer with resectable disease
复制标题
可切除疾病的 IV 期直肠癌的短程放疗
DOI：
10.1007/s12094-021-02647-0
复制
发表时间：
2021
影响因子：
3.4
通讯作者：
E. Guinó
中科院分区：
文献类型：
--
作者：
M. Cambray;J. González;M. Macià;F. Losa;G. Soler;R. Frago;J. Mullerat;J. Castellví;E. Guinó
引言IV期直肠癌的可切除性是一个具有挑战性的问题，因为整个疾病的根治性治疗是困难的。手术和化疗（CT）发挥了毋庸置疑的作用，但盆腔放疗（RT）的贡献是不是很clear.MethodsIn 2009年，我们建立了一个前瞻性的治疗方案，包括CT，短期的术前放疗（SCRT）与手术的原发肿瘤和所有的转移location.ResultsForty患者。8例（20%）患者因显著合并症未接受CT。22例（55%）患者可能进行根治性手术治疗。平均随访42.81个月（3.63-105.97）。24个月和36个月的总生存率分别为71.4%和58.2%。有良好的局部控制的疾病，97.2%的盆腔手术是R 0，并没有局部recurruption.ConclusionIn第四阶段与可切除的转移性疾病，建议的治疗方案似乎非常合适，在精心挑选的患者能够耐受治疗。我们认为盆腔放疗的作用，因为在我们的系列中对疾病有良好的局部控制。
IntroductionStage IV rectal cancer with resectable disease presents challenging issues, as the radical treatment of the whole disease is difficult. Surgery and chemotherapy (CT) play an unquestionable role, but the contribution of pelvic radiotherapy (RT) is not very clear.MethodsIn 2009, we established a prospective treatment protocol that included CT, short-course preoperative radiotherapy (SCRT) with surgery of the primary tumour and all metastatic locations.ResultsForty patients were included. Eight (20%) patients did not receive CT due to significant comorbidities. Radical surgery treatment was possible in 22 (55%) patients. The mean follow-up was 42.81 months (3.63–105.97). Overall survival at 24 and 36 months was 71.4% and 58.2%, respectively. There was good local control of the disease, as 97.2% of pelvic surgeries were R0 and there were no local recurrences.ConclusionIn stage IV with resectable metastatic disease, the proposed therapeutic regimen seems very appropriate in well selected patients able to tolerate the treatment. We bet on the role of pelvic RT, due to the good local control of the disease in our series.